Home / Healthcare/ Johnson & Johnson says to work on India compensation for recalled hip implants

Johnson & Johnson says to work on India compensation for recalled hip implants


Comments / {{hitsCtrl.values.hits}} Views / Wednesday, 12 September 2018 00:00

Facebook

Mumbai (Reuters): Johnson & Johnson (J&J) said on Friday it would work with the Indian government to compensate patients who suffered from artificial hip implants the US healthcare company recalled eight years ago.

Last month, a government panel recommended that J&J pay compensation of at least INR 2 million ($27,812) to each patient who received an ASR hip implant in India, an estimated 4,700 people. The federal government has asked states to help the patients get relief soon.

“We have always been and continue to be fully committed to supporting all ASR patients in India, and the rest of the world,” a J&J spokeswoman said in a statement emailed to Reuters.

“In light of the recent committee report, we are seeking to work with the Indian government to develop an appropriate process for providing further support and compensation for patients in need,” she added.

The ASR hip implants were recalled in 2010 after data suggested they failed at a higher-than-expected rate.

In 2013, the firm agreed to pay nearly $2.5 billion to settle thousands of lawsuits from patients in the United States who said they were injured by the implants.

In India, the company paid $2 million to patients for repeat surgeries and about $250,000 in related diagnostic costs under its ASR reimbursement program, but the government panel criticised J&J for offering no compensation.

About 93,000 people worldwide received ASR implants, the panel said in its report to the government, about 4,700 of them in India.

Metal hip implant systems such as ASR were designed to be more durable than a traditional metal-on-plastic, ball-and-socket design. But many Indian patients suffered adverse reactions to the implant, the panel said.

J&J entered the Indian market in 1947 when it started selling its now-ubiquitous baby powder. The company has in recent years faced issues such as price caps on medical devices.

 


Share This Article

Facebook Twitter


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

Come, let us build!

Friday, 26 April 2019

It was the best of times; it was the worst of times. Best because Sri Lanka was united in what it did well: being at peace, on an extended sabbatical, pursuing the absence of conflict – even mindlessly – and enjoying the fruit of island life. Wor


Black Easter

Friday, 26 April 2019

To Sri Lankan Christians, Easter this year was a day of God where demons reigned. It can be considered an unfortunate day in which the country was plunged again into the uncivilised wretchedness that prevailed in the country during the violent confli


Explaining Sri Lanka’s new Emergency Regulations on ‘publication’

Friday, 26 April 2019

Sri Lanka’s President issued a new set of Emergency Regulations on 22 April. This note explains the contents of Emergency Regulation 15, which concerns the ‘control of publications’, and certain other regulations relevant to publication. There


A secular public space is essential for the safety and wellbeing of all

Friday, 26 April 2019

The heart is heavy and the pen is slow. The environment is thick with the shared sorrow of many. Pain and suffering caused by deaths of hundreds and maiming of more on Easter of 2019 will linger for the rest of our lives. But life must go on and we m


Columnists More